There are 859 resources available
289MO - Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Presenter: Xiaotian Han
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Thoracic cancer
Resources:
Webcast
290MO - Efficacy and safety of topical sintilimab administration in conjunction with CRT and Californium-252 neutron brachytherapy in first-line advanced gynecological squamous cell carcinoma patients
Presenter: Xiaoling Li
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
74MO - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Presenter: Do-Youn Oh
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
75MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Presenter: Yasutoshi Kuboki
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 288MO, 289MO and 290MO
Presenter: Alexandra Leary
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
76MO - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Presenter: Tom Wei-Wu Chen
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
77MO - A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
Presenter: Rujiao Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast